021-51111890
购物车（）
sales@molnova.cn
SNDX-5613
CAS No. 2169919-21-3
SNDX-5613 ( —— )
产品货号. M23982 CAS No. 2169919-21-3
SNDX-5613 是 Menin-MLL 的有效且特异性抑制剂（Ki 为 0.149 nM，基于细胞的 IC50 为 10-20 nM）。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥940 | 有现货 |
|
| 5MG | ￥1539 | 有现货 |
|
| 10MG | ￥2717 | 有现货 |
|
| 25MG | ￥4427 | 有现货 |
|
| 50MG | ￥6305 | 有现货 |
|
| 100MG | ￥8262 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥2166 | 有现货 |
|
生物学信息
-
产品名称SNDX-5613
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述SNDX-5613 是 Menin-MLL 的有效且特异性抑制剂（Ki 为 0.149 nM，基于细胞的 IC50 为 10-20 nM）。
-
产品描述SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias. (In Vivo):Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.
-
体外实验——
-
体内实验Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.
-
同义词——
-
通路Chromatin/Epigenetic
-
靶点Histone Demethylase
-
受体Menin-MLL
-
研究领域——
-
适应症——
化学信息
-
CAS Number2169919-21-3
-
分子量630.82
-
分子式C32H47FN6O4S
-
纯度>98% (HPLC)
-
溶解度DMSO:41.67 mg/mL (66.06 mM; Need ultrasonic)
-
SMILESO=C(C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(C3)CCN(CC4)C[C@H]5CC[C@@H](CC5)NS(=O)(CC)=O)N(C(C)C)CC
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).
产品手册
关联产品
-
UNC3866 TFA(1872382-...
根据 AlphaScreen 测定，UNC3866 TFA 是 CBX7-H3 相互作用的有效拮抗剂。
-
ORY-1001 dihydrochlo...
ORY-1001 diHClide (RG-6016, Ladademstat) 是一种高效、选择性的赖氨酸特异性去甲基酶 KDM1A (LSD1) 抑制剂，IC50 为 18 nM。
-
SAH-EZH2
EZH2/EPP interaction inhibitor (Kd = 320 nM). Suppresses EZH2 expression and H3K27 trimethylation by PCR2 complex. Arrests proliferation and induces monocyte to macrophage differentiation of MLL-AF9 leukemia cell line.
